Dupont Capital Management Corp Fibrogen Inc Transaction History

Dupont Capital Management Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 28, 2021	SELL	$37.09 - $48.97 $186,191 - $245,829	-5,020 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$40.47 - $45.5 $203,159 - $228,410	5,020 New	5,020 $206,000
Q2 2020 Jul 24, 2020	SELL	$32.57 - $42.83 $254,078 - $334,116	-7,801 Closed	0 $0
Q4 2019 Jan 27, 2020	SELL	$34.58 - $48.06 $301,537 - $419,083	-8,720 Reduced 52.78%	7,801 $335,000
Q3 2019 Oct 28, 2019	SELL	$36.98 - $48.45 $53,214 - $69,719	-1,439 Reduced 8.01%	16,521 $611,000
Q2 2019 Jul 30, 2019	BUY	$35.13 - $55.53 $73,773 - $116,613	2,100 Added 13.24%	17,960 $811,000
Q4 2018 Feb 01, 2019	BUY	$37.97 - $60.16 $313,366 - $496,500	8,253 Added 108.49%	15,860 $734,000
Q3 2018 Nov 05, 2018	BUY	$56.3 - $67.25 $428,274 - $511,570	7,607 New	7,607 $462,000
Q1 2018 May 02, 2018	SELL	$45.35 - $61.65 $793,171 - $1.08 Million	-17,490 Closed	0 $0
Q4 2017 Jan 31, 2018	SELL	$41.95 - $60.1 $249,896 - $358,015	-5,957 Reduced 25.41%	17,490 $829,000
Q3 2017 Oct 31, 2017	BUY	$33.4 - $53.9 $783,129 - $1.26 Million	23,447	23,447 $1.26 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.